RxDoctor Payments Data

Richard McCurdy, MD

Cardiovascular Disease · Media, PANPI 1093764540

Payments from drug & device makers

$986in general payments, 2019–2025

Across 26 payments — averaging $37.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$236
  • Heartflow, Inc.$157
  • Boston Scientific$146
  • Abbott$138
  • Johnson & Johnson$137
  • E.r. Squibb & Sons, L.L.C.$98
  • plus $72 from 3 others

What the payments were for

  • Food & beverage$986100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen6$236
Heartflow, Inc.1$157
Boston Scientific5$146
Abbott2$138
Johnson & Johnson6$137
E.r. Squibb & Sons, L.L.C.2$98
Medtronic(2 entities)2$25
Novartis1$24
Pfizer1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$986 in reported general payments places this provider in the 35th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$424,107
Medicare patients
1,331
Services billed
5,623

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban686$763,526
XareltoRivaroxaban249$316,667
EntrestoSacubitril/Valsartan195$280,589
JardianceEmpagliflozin157$187,884
Repatha SureclickEvolocumab81$70,082
FarxigaDapagliflozin Propanediol47$59,402
Praluent PenAlirocumab38$35,818
Repatha SyringeEvolocumab49$32,704
Metoprolol Succinate955$17,723
MultaqDronedarone Hcl20$17,632
VascepaIcosapent Ethyl31$17,038
Ezetimibe374$12,221
Rosuvastatin Calcium659$10,530
Nifedipine ErNifedipine234$9,706
Atorvastatin Calcium637$9,439

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$763,526686 claims
Johnson & JohnsonXarelto$137$316,667249 claims
NovartisEntresto$24$280,589195 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Media

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →